Effect of the closure of mesenteric defects in laparoscopic Roux-en-Y gastric bypass: a prospective study.
CONCLUSION: The closure of MDs eliminated the risk of IH in half of the operated patients of LRYGB in this series. PMID: 31521564 [PubMed - as supplied by publisher]
Publication date: Available online 24 September 2020Source: Journal of Visceral SurgeryAuthor(s): M.K. Collard, A. Torcivia, L. Genser
The objective of this study is to quantify the magnitude of association between putative weight-promoting medications and 3-year weight change in a diverse cohort of postmenopausal women in the Women's Health Initiative (WHI). Methods: This is a prospective observational cohort study, considering 40 sites in the WHI and a cohort of seventy six thousand two hundred fifty-two postmenopausal women aged 50-79 years, with weight measured at both baseline and 3 years, in the WHI-Observational Study. Body mass index (BMI) and waist circumference (WC) were measured at baseline and 3 years. An in-clinic medication inventory iden...
Conclusions: 17β-Estradiol exhibits the greatest efficacy on the attenuation of obesity with the least harmful effect on skeletal muscle in a model of menopause with obesity, yet its effect on the treatment of hyperlipidemia is inferior to those of standard lipid-lowering agents.
Conclusions and Relevance: Lacking strong evidence indicating significant patient risk for vaginal laser treatment of GSM, the FDA safety communication appears unsubstantiated and implies gender bias. Identified complications suggest most reported “adverse events” represent lack of treatment effect. The well-documented benefits and low risk of adverse event suggest laser therapy for GSM is reasonable with appropriate pretreatment counseling. Additional randomized, well-controlled clinical trials are needed to further elucidate both the safety and efficacy of this nonhormone therapy.
Publication date: 26 September–2 October 2020Source: The Lancet, Volume 396, Issue 10255Author(s): Andrew W Horne, Katy Vincent, Catherine A Hewitt, Lee J Middleton, Magda Koscielniak, Wojciech Szubert, Ann M Doust, Jane P Daniels, Suraiya Abdi, Santanu Acharya, Shamma Al-Inizi, Elizabeth Ball, Andrew Baranowski, Nadia Bhal, Kalsang Bhatia, Siladitya Bhattacharya, Judy V. Birch, Tyrone Carpenter, Tony Chalhoub, Ying C. Cheong
Publication date: Available online 24 September 2020Source: Journal of Acupuncture and Meridian StudiesAuthor(s): Abedini Maryam, Aminzadeh Fariba, Manshoori Azita, Bakhtar Babak, Sadeghi Tabandeh
Publication date: October 2020Source: Archives of Cardiovascular Diseases Supplements, Volume 12, Issues 2–4Author(s): C. Pop, L. Stoicescu, G. Stefan, J. Dhot, V.A. Balteanu, B. Lauzier, C. Morgovan, C. Mogosan, S. Ghibu
Publication date: October 2020Source: Archives of Cardiovascular Diseases Supplements, Volume 12, Issues 2–4Author(s): L. Cornuault, S. Guimbal, P.L. Hollier, C. Chapouly, A.P. Gadeau, T. Couffinhal, M.A. Renault
Authors: Montefusco V, Mussetti A, Sala MR, Martinelli G, Cerchione C Abstract Proteasome inhibitors (PIs) represent a recently developed drug class that inhibit the ubiquitinproteasome system, thus interfering with the intracellular machinery who has the duty of misfolded proteins disposal. Myeloma plasma cells are structurally aimed at the production of large quantities of immunoglobulins. This explains their vulnerability to any perturbation of intracellular protein homeostasis. Bortezomib is the first-in-class PI and nowadays, in combination with other compounds, is the cornerstone of multiple myeloma (MM) trea...
In conclusion, although EUS-PD remains a challenging procedure with a high risk of adverse events such as pancreatic juice leakage, perforation, and severe acute pancreatitis, the procedure seems to be a promising alternative for PD drainage in patients with altered anatomy or unsuccessful endoscopic retrograde pancreatography. PMID: 32967409 [PubMed - as supplied by publisher]